AMI Asset Management’s Albany Molecular Research Inc AMRI Stock Holding History

AMI Asset Management’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-735,876	Closed	-$16M	–	79
2017 Q2	$16M	Buy	735,876 +30,383	+4%	+$551K	1.14%	34
2017 Q1	$9.9M	Sell	705,493 -97,236	-12%	-$1.59M	0.75%	51
2016 Q4	$15.1M	Sell	802,729 -50,275	-6%	-$855K	1.11%	42
2016 Q3	$14.1M	Sell	853,004 -23,439	-3%	-$347K	0.97%	48
2016 Q2	$11.8M	Buy	876,443 +313,225	+56%	+$4.57M	0.82%	51
2016 Q1	$8.61M	Buy	563,218 +69,745	+14%	+$1.09M	0.59%	55
2015 Q4	$9.79M	Buy	493,473 +113,887	+30%	+$2.16M	0.68%	55
2015 Q3	$6.61M	Buy	+379,586	New	+$7.73M	0.51%	55

Other funds holding AMRI

Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

AMI Asset Management's AMRI Position: Q3 2017 in Review

AMI Asset Management sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 735,876 shares — an estimated $16M sold.

AMI Asset Management first reported a position in AMRI in Q3 2015 and held it in 8 quarters. The position peaked at $16M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

AMI Asset Management reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
AMI Asset Management sold 735,876 Albany Molecular Research Inc shares in Q3 2017, an estimated $16M.
AMI Asset Management first reported a position in Albany Molecular Research Inc in Q3 2015 and held it in 8 quarters.
AMI Asset Management's Albany Molecular Research Inc position peaked at $16M in Q2 2017.
2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on AMI Asset Management's 13F filing for Q3 2017, filed 10 Oct 2017.